Screener
ImmunityBio, Inc. IBRX Reportable Segment — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interest | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
| Net loss attributable to ImmunityBio common stockholders | $(632,782) | $(129,646) |
| Net loss per ImmunityBio common share – basic and diluted | $(0.62) | $(0.15) |
| Weighted-average number of common shares used in computing net loss per share – basic and diluted | 1,026,874 | 853,162 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — net loss?
- ImmunityBio, Inc. (IBRX) reported reportable segment — net loss of -$632.8M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — net loss changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — net loss decreased by 388.0% year-over-year, from -$129.67M to -$632.8M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — net loss?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — net loss has grown at a -5.6% compound annual growth rate (CAGR), from -$417.32M to -$351.47M.
- What does reportable segment — net loss mean?
- This metric represents the total net loss attributable to a specific reportable business segment after all expenses, including taxes and noncontrolling interests, have been accounted for. It serves as the bottom-line performance indicator for the segment's contribution to the overall company's financial results. For clinical-stage companies, this often highlights the cash-burn or investment intensity required to advance specific therapeutic pipelines.
Ask your AI about ImmunityBio, Inc.'s reportable segment — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude